Current Projects

  • Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH)

    • In this topic of research, we have been focussing primarily on the following key areas:

      • Efficacy of the ‘ASIG Algorithm’, combination of yearly blood test NT-proBNP and respiratory function tests, to identify those at risk of SSc-PAH in Australian and international SSc populations
      • Accuracy of risk assessment to determine outcomes in SSc-PAH and therefore identification of those in whom dual and triple PAH therapy is indicated
      • Updated assessment of outcomes among those with SSc-PAH in Australia
      • Role of NT-proBNP alone to predict SSc-PAH

    Publications:
    Brown, Z., D. Hansen, W. Stevens, N. Ferdowsi, L. Ross, A. Quinlivan, J. Sahhar, et al. “Evaluation of the European Society of Cardiology (Esc) Risk Assessment Score in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (Ssc-Pah).” Arthritis Care Res (Hoboken)  (Mar 24 2024). https://doi.org/10.1002/acr.25328. https://www.ncbi.nlm.nih.gov/pubmed/38523256.
    Brown, Z. R., and M. Nikpour. “Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis: Now or Never!”. Eur J Rheumatol 7, no. Suppl 3 (Oct 2020): S187-S92. https://doi.org/10.5152/eurjrheum.2020.19114. https://www.ncbi.nlm.nih.gov/pubmed/33164734.
  • Scleroderma Interstitial lung disease (SSc-ILD)

    • Interstitial lung disease is a common manifestation of scleroderma, occurring in up to 70% of patients. It is not always progressive but in a multi-national cohort study, ILD was found to be the principal cause of death in 21% of and contributed to mortality in a further 11-14%. The burden of SSc ILD is substantial for patients, their families and our health system. As therapies to treat SSc ILD can be associated with toxicity, identification of patients with progressive disease who are most likely to benefit from therapy from those with stable disease is crucial.
    • ASIG researchers have used data from the Australian Scleroderma Cohort Study to determine
      • predictors of progression of ILD and mortality including the utility of
        • serial pulmonary function
        • baseline high resolution CT (HRCT) chest
        • serum biomarkers
      • the efficacy and tolerance of therapies for ILD
      • To further determine predictors of progression of ILD and to assess response to novel therapies, ASIG has established an HRCT chest repository which will enable
      • linkage of radiologic data to clinical and biospecimen data
      • application of artificial intelligence platforms to analyse HRCT scans

    Publications:
    Owen C, Ngian G-S, Moore O, et al. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis –associated interstitial lung disease: results from the Australian Scleroderma Cohort Study. Clinical and Experimental Rheumatology. 2016. Accepted 20th December 2015. https://doi.org/10.1093/rheumatology/keae110
    Parker MJS, Jee AS, Hansen D, et al. Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis, Rheumatology, 2024;, keae110, DOI: 10.1093/rheumatology/keae110.
    Jee AS, Stewart I, Youssef P, et al. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study. Arthritis Rheumatol. 2023 Aug;75(8):1424-1433. doi: 10.1002/art.42491.
    Moore O, Goh N, Corte T, et al. Extent of Disease on High-Resolution CT Lung is a Predictor of Decline and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease. Rheumatology (Oxford) 2013 Jan;52(1):155-60. DOI: 10.1093/rheumatology/kes289
    Moore O, Proudman S, Goh N,et al. Quantifying Change in Pulmonary Function as a Prognostic Marker in Systemic Sclerosis-Related Interstitial Lung Disease. Clin and Exp Rheum, 2015 PMID: 26243401
    Fairley JL, Hansen D, Ross L, et al. Clinical characteristics and survival of combined pulmonary arterial hypertension and interstitial lung disease in systemic sclerosis. Accepted for publication, Arthritis Res & Ther 29/04/2023. DOI: 10.1186/s13075-023-03059-x
    Morrisroe K, Hansen D, Stevens W, et al. Progressive pulmonary fibrosis and its impact on survival in systemic sclerosis related interstitial lung disease. Rheumatology (Oxford). 2023 Sep 19:kead491. doi: 10.1093/rheumatology/kead491. Epub ahead of print. PMID: 37725359. DOI: 10.1093/rheumatology/kead491
    Morrisroe K, Stevens W, Sahhar J, et al. The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology (Oxford). 2020 Aug 1;59(8):1878-1888. doi: 10.1093/rheumatology/kez532. PMID: 31740961.
    Hao Y, Hudson M, Baron M, et al. Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. Arthritis Rheumatol. 2017 May;69(5):1067-1077. DOI: 10.1002/art.40027
  • Exploring heart health, physical function and wellbeing in scleroderma

    • Dr Jessica Fairley is completing a PhD investigating cardiopulmonary disease and physical function in people living with scleroderma. Jessica leads the Scleroderma HeartBeat Study, a controlled observational study exploring cardiovascular health and exercise capacity in people with scleroderma compared to age- and sex-matched controls in collaboration with St Vincent’s Institute for Medical Research and the Baker Heart and Diabetes Institute. Furthermore, Jessica is currently collaborating with the National Coronial Information System to explore organ damage in scleroderma Jessica has also completed a number of projects using data from the Australian Scleroderma Cohort Study exploring different facets of cardiac, pulmonary and skeletal muscle disease in scleroderma, as well as patient-reported outcomes including fatigue and physical disability.

    Publications:
    Fairley JL et al, Frequency and implications of malnutrition in systemic sclerosis. Rheumatology Oxford, 2024. https://doi.org/10.1093/rheumatology/keae209
    Fairley JL et al, Contribution of left ventricular diastolic dysfunction to survival and breathlessness in systemic sclerosis–associated interstitial lung disease. J Rheumatol, 2024. https://doi.org/10.3899/jrheum.2023-0801
    Fairley JL et al, Proximal weakness and creatine kinase elevation in systemic sclerosis: Clinical correlates, prognosis and functional implications. Sem Arthritis Rheum, 2024. https://doi.org/10.1016/j.semarthrit.2024.152363
    Fairley JL et al, Prognostic and functional importance of both overt and subclinical left ventricular systolic dysfunction in systemic sclerosis. Sem Arthritis Rheum, 2024. DOI: DOI: 10.1016/j.semarthrit.2024.152443
  • Damage Index

    • Developed by a working group of the Scleroderma Clinical Trials Consortium (SCTC) using a combination of consensus (survey of international experts across a range of disciplines, input from patient partners and face-to-face discussions) and data driven methodology (using separate validation and derivation cohorts), the SCTC-Damage Index (SCTC-DI) is a 23-item weighted instrument specifically designed to identify and quantify organ damage in scleroderma. Potential applications of the SCTC-DI include use as an endpoint in observational studies and interventional studies, and to enrich clinical trials for patients without substantial existing damage who are most likely to benefit from treatment. As a first of its kind, the SCTC-DI will certainly attract a great deal of attention from the scientific community and be used in a variety of setting and future studies.

    Publications:
    Ferdowsi N, Huq M, Stevens W, et al. Development and validation of the scleroderma clinical trials consortium damage index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Ann Rheum Dis 2019; 78: 806. DOI: 10.1136/annrheumdis-2018-214764
    Tay T, Huq M, Ferdowsi N, et al. Early accrual of organ damage in systemic sclerosis: rationale for development of a disease damage index. J Scleroderma Relat Disord 2017; 2(2):127-134. DOI: 10.5301/jsrd.5000239.
  • Burden of disease in systemic sclerosis

    • This work comprehensively quantified the burden of scleroderma in Australia including its impact on healthcare utilisation, work and patient-reported health-related quality of life.
    • Its impact occurs early in the scleroderma disease course and is seen across all of facets of the individual’s life including impact on work, daily activities, and quality of life.
    • Raising awareness of these issues and identifying potential modifiable risk factors may help in reducing this burden and improving patient centred care and quality of life.

    Publications:
    Morrisroe K, Sudararajan V, Stevens W, etal. Work productivity in systemic sclerosis, its economic burden and association with health-related quality of life. Rheumatology (Oxford). 2018 Jan 1;57(1):73-83. DOI: 10.1093/rheumatology/kex362
    Morrisroe K, Stevens W, Sahhar J, et al. Quantifying the direct health care cost of systemic sclerosis: a comprehensive data linkage study. Medicine (Baltimore). 2017 Dec;96(48). DOI: 10.1097/MD.0000000000008503.
    Morrisroe K, Hudson M, Baron M, et al. Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. Clin Exp Rheumatol. 2018 Jul 36, Suppl113(4): 53-60. PMID: 30183603
  • The ASIG Pulmonary Arterial Hypertension (PAH) risk assessment algorithm

    • This work arose in response to the need for a sensitive, cost-effective method of screening for pulmonary arterial hypertension (PAH) which occurs in up to 15% of patient with scleroderma. PAH is one of the leading causes of mortality and is one of the major determinants of the substantial healthcare costs associated with scleroderma. International guidelines recommend annual screening for PAH in all patients with scleroderma as while early detection can be challenging, screening is associated with better outcomes. Transthoracic echocardiogram (TTE) alone is insufficiently sensitive for identifying patients at risk of PAH who should be referred for right heart catheterisation (RHC), the gold standard for PAH diagnosis. The DETECT algorithm involved more disease-related features and is still dependent on a TTE.
    • ASIG researchers derived and then validated the ASIG PAH algorithm based on the biomarker, serum NT-proBNP (a peptide released from cardiac myocytes) and pulmonary function tests to measure FVC % predicted and DLCO % predicted.
    • A comparison of the predictive accuracy of the ASIG and DETECT screening algorithms for SSc-PAH with the commonly used ESC/ERS guidelines showed that both algorithms outperform the ESC/ERS guidelines, detecting all patients with PAH. Compared with the DETECT algorithm, the ASIG algorithm had the highest specificity (54.5%) and performed equally well in sensitivity (100%) and NPV (100%) and a little better in PPV (60%).
    • The ASIG algorithm was also associated with cost savings substantially reducing the number of TTE and RHC required compared with TTE.
    • Medicare now allows all patients with SSc to have up to two reimbursed blood tests for NT-proBNP each year as part of PAH screening.
    • The ASIG PAH risk assessment calculator based on the ASIG screening algorithm can be accessed here to assess a patient’s risk for PAH.

    Publications:
    Quinlivan, A. et al. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. Intern Med J 45, 1134-1140, DOI: 10.1111/imj.12890 (2015).
    Hao, Y. et al. A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 17, 7, DOI: 10.1186/s13075-015-0517-5 (2015).
    Thakkar, V. et al. The Inclusion of N-Terminal pro-Brain Natriuretic Peptide in a Sensitive Screening Strategy for Systemic Sclerosis-Related Pulmonary Arterial Hypertension: a cohort study. Arthritis Res Ther. 2013;15(6):R193. DOI: 10.1186/ar4383
    Thakkar, V. et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 14, R143, DOI: 10.1186/ar3876 (2012).
  • Development of the Scleroderma Clinical Trials Consortium Activity Index

    • As members of the Scleroderma Clinical Trials Consortium, ASIG researchers have been working with a global group of scleroderma experts to develop a Scleroderma Disease Activity Index. Prof Mandy Nikpour has been the co-chair of the international Scleroderma Clinical Trials Consortium Activity Index Working Group since 2017. The Activity Index has been designed to be used as a clinical research tool to measure the current burden of scleroderma that may be reversible with treatment. ASIG researchers developed the Activity Index with input from their global network of research collaborators.
    • As part of the development of the Activity Index, ASIG researchers have examined how assessment of patient symptoms can assist in the measurement of scleroderma disease activity. ASIG data has been used to evaluate the role of routine blood tests such as measurement of the C-reactive protein level, can help in the quantification of disease activity.
    • ASIG data was used to validate the final Activity Index, which has recently been published. Further studies are currently underway, testing of the Activity Index’s performance both in the Australian Scleroderma Cohort Study and international scleroderma studies.

    Publications:
    Ross L, Hansen D, Proudman S et al Development and initial validation of the novel Scleroderma Clinical Trials Consortium Activity Index Arthritis Rheumatol 2024 DOI: 10.1002/art.42939
    Ross L, Stevens W, Wilson M et al Can patient-reported symptoms be used to measure disease activity in systemic sclerosis? Arthritis Care Res 2020 72(10) 1459-1465 DOI: 10.1002/acr.24053